Skip to main content
PLOS Global Public Health logoLink to PLOS Global Public Health
. 2023 Dec 5;3(12):e0001813. doi: 10.1371/journal.pgph.0001813

The feasibility, acceptability, and preliminary impact of real-time monitors and SMS on tuberculosis medication adherence in southwestern Uganda: Findings from a mixed methods pilot randomized controlled trial

Angella Musiimenta 1,2,*, Wilson Tumuhimbise 1,2, Esther C Atukunda 1, Aaron T Mugaba 1,2, Nicholas Musinguzi 1, Conrad Muzoora 1, David Bangsberg 3, J Lucian Davis 4,5,6, Jessica E Haberer 7,8
Editor: Megan Coffee9
PMCID: PMC10697590  PMID: 38051699

Abstract

We conducted a pilot randomized controlled trial among patients initiating treatment for drug-sensitive tuberculosis (TB). Participants received real-time electronic adherence monitors and were randomized (1:1:1) to: (i) daily SMS (reminders to TB patients and notifications to social supporters sent daily for 3 months, then triggered by late or missed dosing for 3 months); (ii) weekly SMS (reminders to TB patients and notifications to social supporters sent weekly for 3 months, then triggered by late or missed dosing for 3 months); or (iii) control (no SMS). Feasibility was mainly verified by the technical function of the intervention at Month 6. The primary outcome was percent adherence as ascertained by the real time monitor. Quantitative feasibility/acceptability data were summarized descriptively. Percentage adherence and adherence patterns were assessed and compared by linear regression models. Qualitative acceptability data was collected through interviews and analyzed using content analysis. Among 63 participants, the median age was 35 years, 75% had no regular income, and 84% were living with HIV. Feasibility was demonstrated as most of the daily [1913/2395 (80%)] and weekly [631/872 (72%)] SMS reminders to TB patients were sent successfully. Also, most of the daily [1577/2395 (66%)] and weekly [740/872 (85%)] SMS notifications to social supporters and adherence data (96%) were sent successfully. Challenges included TB status disclosure, and financial constraints. All patients perceived the intervention to be useful in reminding and motivating them to take medication. Median adherence (IQR) in the daily SMS, weekly SMS, and control arms was 96.1% (84.8, 98.0), 92.5% (80.6, 96.3), and 92.2% (56.3, 97.8), respectively; however, differences between the intervention and control arms were not statistically significant. Real-time monitoring linked to SMS was feasible and acceptable and may have improved TB medication adherence. Larger studies are needed to further assess impact on adherence and clinical outcomes.

Trial registration. ClinicalTrials.gov registration number: NCT03800888. https://ichgcp.net/clinical-trials-registry/NCT03800888.

Introduction

Worldwide, nearly 10 million people develop tuberculosis (TB) and nearly 2 million people die from TB annually [1]. Low income countries account for more than 90% of TB cases and deaths [2]. Uganda faces a high burden of TB and is listed among the 30 countries with the highest rates of TB and TB/HIV co-infection [2], with an annual TB incidence of 196 (95% CI 117–296) per 100,000 overall and 65 (95% CI 39–98) per 100,000 people living with HIV [3]. In Uganda, an estimated 223 people acquire TB daily and 30 deaths due to TB occur [3]. Importantly, TB is the number one cause of death among individuals living with HIV [4]. While TB treatment is freely available in Uganda, treatment adherence challenges remain [5]. Causes of non-adherence to TB medication include depression and alcohol [6], lack of transport to the clinics to pick up drugs, [5] and forgetfulness [7]. Non-adherence to TB medication contributes to disease transmission, drug resistance, and treatment failure [810].

The World Health Organization (WHO) has long recommended directly observed therapy (DOT), which requires taking medication under the supervision of a health worker or trained treatment supporter [11]. However, the implementation of DOT has been limited in many settings for several reasons; DOT requires a significant time commitment from people living with TB, healthcare workers, and treatment supporters and places financial burdens on TB patients when they travel to the clinic for DOT administration [12,13]. DOT may also infringe on TB patients’ autonomy [14]. Moreover, for preventing disease relapse and acquired drug resistance, DOT may not perform better than self-administered therapy [15]. Alternative, novel methods are needed for effective management of TB medication adherence especially in settings where DOT’ implementation is challenging and/or undesirable. Recognizing this need, the WHO now recommends using digital adherence technologies to support TB medication adherence as part of its End TB Strategy [16]. Examples of such technologies include SMS reminders and digital medication monitors (i.e., devices that send signals when opened as a proxy for taking medication). Importantly, real-time adherence monitors can enable the provision of timely interventions to address non-adherence before TB patients experience the consequences of non-adherence. Real-time adherence monitoring linked with SMS reminders has been shown to be feasible and acceptable [17] and to improve adherence to antiretroviral therapy (ART) [18]. However, few quality studies have investigated these technologies for TB medication adherence, especially in low resource settings, and the modest prevailing studies report mixed results [1923]. In addition, the role for SMS in activating social support among TB patients has not been well studied, and research is needed on the integration of supportive SMS notifications to real-time monitoring of TB medication adherence.

We therefore conducted a pilot randomized controlled trial (RCT) investigating the use of: i) real-time adherence monitors, ii) SMS as adherence reminders to TB patients, and iii) SMS notifications to their social supporters (i.e., friends or family who have helped them with medication or other needs previously) to support TB medication adherence in southwestern Uganda. We previously published formative qualitative findings from the current study demonstrating that real-time adherence monitors and SMS can potentially enhance TB medication adherence by reminding them to take TB medication, and giving them opportunities to demonstrate their commitment to medication adherence through monitoring [24]. Participants also reported that SMS notifications to social supporters can motivate medication adherence by creating a personal sense of commitment to adhere to medication in response to the helping hand extended by social supporters [5]. The current paper reports on the feasibility, acceptability and the preliminary impact of this intervention composed of a real-time device that monitors how TB patients take their medication, SMS reminders to patients and SMS notifications to their social supporters.

Materials and methods

Ethics statement

All participants provided signed informed consent before study participation. The institutional review committees of Mbarara University of Science and Technology (Protocol number: 16/10–16), and the Uganda National Council for Science and Technology (Protocol number: HS 2189).

Study design and setting

This study reports the quantitative and qualitative results from a pilot RCT among people with drug-sensitive TB recruited from the TB Clinic within Mbarara Regional Referral Hospital (MRRH) in southwestern Uganda. The TB clinic at MRRH provides care to an estimated 600 TB patients annually. At the TB Clinic, newly diagnosed TB patients receive free TB medication and are counseled about the benefits of TB medication. The DOT approach is not employed for monitoring medication adherence at MRRH due to the costs for both TB patients and within the healthcare system. Instead, TB patients self-administer therapy with isoniazid, rifampin, pyrazinamide, and ethambutol for two months (2RHZE; intensive phase), followed by isoniazid plus rifampin for four months (4HR; continuation phase). The clinic verbally encourages patients to adhere to their medication. The TB treatment regimens use fixed-dose combination tablets TB patients return to the TB Clinic every two weeks for the first two months, including for a sputum examination to ensure conversion to negative results prior to the continuation phase. Those with positive test result receive GeneXpert to exclude rifampicin resistance. Treatment can be extended up to a full year to account for missed medication refills or doses.

Selection of study participants

Between May 2019 and June 2020, we randomly recruited TB patients if they met the following inclusion criteria: a) being age 18 years and older, b) being newly diagnosed with TB per clinic records (within a month of initiating treatment), b) initiating drug-sensitive TB treatment at the MRRH TB Clinic, c) living in Mbarara District (within 20 km of MRRH), d) knowing how to use SMS, e) owning a cellphone for personal use, and f) having reliable cellular network at home. Before enrollment in the study, cellular reception was assessed by the research assistants who escorted participants in their homes to check the signal of the networks supported by the technology used in this study either MTN or Airtel. The exclusion criteria were an unwillingness or inability to have cellular reception confirmed at home and/or to give consent to be in the study. Inclusion criteria for social supporters were a) being age 18 years and older, b) living in the Mbarara District, c) having an ongoing relationship with the TB patients(e.g., friend or family member), d) owning a cell phone for personal use, and e) knowing how to use SMS. The only exclusion criterion was being unwilling or unable to give consent.

The intervention technology

The intervention was composed of a real-time device that monitors how TB patients take their medication as described elsewhere [17,24], the real-time adherence monitor (Wisepill Technologies, Cape Town, South Africa) is a medication container that holds up to 28 tablets of RHZE. The real-time adherence monitor has an internal modem and subscriber identity module (SIM) card enable the device to send a real-time mobile signal to a secure web server (hosted in South Africa) by General Packet Radio Service. When opened to take pills, the device records a date-and-time stamp; receipt of this signal is interpreted as a proxy for taking medication. The device stores records of openings in the event of inadequate mobile network coverage and sends them when the network becomes available. The monitor additionally sends a daily “heartbeat” to confirm device functionality. The monitor can be charged using electricity or a solar device; its battery life is typically six months. Additionally, the intervention involved SMS reminders (scheduled and/or triggered by missed or delayed dosing) to TB patients to help them take their medications, as well as SMS notifications to their social supporters to provide the TB patients with assistance if possible. The content of SMS reminders and notifications were determined by each participant. The default message for both TB patients and social supporters was “This is your reminder.” SMS were sent from Wisepill technologies at no cost to participants at their specific time of taking medication.

Outcome measures

The primary outcome was percent adherence ascertained by the real time monitor. Secondary outcomes were feasibility which was verified by the technical function of the intervention including the number of SMS sent as planned, number of SMS not sent as planned, number of SMS sent later due to a delay or absence of the corresponding signal, data loss by the real-time monitor, monitor malfunctioning, taking medication from other sources, and opening the device without taking medication. Acceptability of the intervention was verified by the participant’s preference of SMS type and frequency, ease of use of the real-time monitor, possibility of unintended TB status disclosure.

Study procedures

TB patients were followed for six months. A random number generator (random allocation was generated by the study coordinator) and the CONSORT diagram and the CONSORT checklist (S1 Checklist) (Fig 1 below) were used to determine study arm assignments by the study team. After screening and consenting, all participants received a real-time adherence monitoring device and were randomized 1:1:1 as follows:

Fig 1. CONSORT diagram to illustrate participant flow in the study.

Fig 1

  1. Daily SMS + real-time adherence monitor -> triggered SMS (‘daily SMS arm’): Daily SMS reminders and notifications were sent to the TB patients depending on their specific time of medication taking and social supporter participants, respectively, for the first three months. For the next three months, SMS reminders and notifications were sent only if the monitor was not opened within an hour of the expected time.

  2. Weekly SMS + real-time adherence monitor -> triggered SMS (weekly SMS arm): Weekly SMS reminders and notifications were sent for the first three months to TB patients and social supporter participants, respectively. For the next three months, SMS reminders and notifications were sent only if the monitor was not opened within an hour of the expected time.

  3. Real-time adherence monitoring only (control arm): No SMS were sent to TB patients or social supporter participants.

Social supporters were identified by study participants at enrollment and were enrolled into the study at the same time with the patients TB patients. Social supporters were generally encouraged to provide support (e.g. medication reminders, counseling, or transport to the clinic) necessary for enabling study participants take their medication well, if possible.

To manage potential strain on relationships and harmonize expectations [25], the research assistants (WT and ATM) provided orientation to TB patients and social supporters at recruitment in which we clarified their roles and highlighted the potential negative effect of non-responsiveness (not taking medication as expected) on relationships.

Data collection

Study participants completed baseline questionnaires (S1 Text) regarding socio-demographics, health, depression [26], food insecurity [27], alcohol use [28], social support [29], TB stigma [30], and socioeconomic status [30]. Adherence data was comprised of signals sent to the study server after opening the real-time adherence monitor. Feasibility data was obtained by tracking SMS sent and received, and monitor and battery functionality. Participant opinion on feasibility and acceptability data was also captured through the study exit pilot-tested questionnaires and qualitative interviews. The development of the questionnaires and interview guide was informed by the Unified Theory of Acceptance and Use of Technology (UTAUT) model [31]. At study exit (month 6), authors WT and ATM (male study research assistants trained in qualitative research, research ethics and Data management with a PhD and MBA respectively) conducted semi-structured, face to face in-depth interviews with TB patients in a private space at a research office near the MRRH until reaching thematic saturation at the 30th participant. Prior to data collection, the researchers had interacted with the participants at enrollment. Each interview lasted between 30 and 60 minutes and was conducted in the local language (Runyankole), digitally recorded, transcribed, and translated to English. The interviewers elicited participants’ experiences of using each component of technologies (real-time monitor, SMS reminders for TB patients, and SMS notifications for social supporters) including benefits and challenges related to the technologies. Following each interview, author AM (with support from JEH and JLD) reviewed transcripts for quality, clarity, and detail.

Analysis

Feasibility and acceptability data were summarized descriptively. In the primary dataset for assessment of adherence, adherence was computed for each participant as the total number of device openings divided by the total number of study follow-up days, excluding days when a participant was considered not to have used the device (e.g., when the device was non-functional as evidenced by no device heartbeat). Adherence data for TB patients who died was included up until death; data were also excluded at loss to follow-up (at the onset of missing data), which was defined as having no contact or adherence data for two months per protocol analysis. Participants were excluded if they voluntarily withdrew from the study or declined to use the adherence monitor. SMS data for TB patients was determined by the Wisepill device in regards to SMS reminders that were sent as planned, those not sent or delayed due to technical challenges like poor network and those sent due to a delay or absence of the corresponding signal. In a secondary analysis, days between loss to follow-up and study completion were considered non-adherence. To assess the effect of each intervention on adherence compared to the control, we used linear regression models with robust standard errors, given the pilot nature of the RCT and the potential for residual confounding in a small sample size. First, we built univariable models considering all potential confounders, which included age, gender, marital status, type of residence, disclosure of TB status to anyone other than their healthcare provider, severe food insecurity, alcohol use, stigma, social support, depression, HIV status, social economic status, study phase (less or equal to 2 months of treatment vs more than 2 months of treatment) and level of education [32] and controlled for the study arm. In the multivariable model, we considered those confounders with a univariable p value <0.2. Analysis was conducted in Stata version 13. In both primary and secondary analysis, the statistician was not blinded to allocation assignments since this was an open label trial.

Qualitative data was analyzed using content analysis [33] to generate categories summarizing TB patients’ experiences of using the technologies, focusing on perceived usefulness and challenging issues counting for effort, social influences and facilitators. AM assembled a codebook from the identified categories, using an iterative process, which included developing codes, writing operational definitions, and selecting illustrative quotes. AM then applied codes using NVIVO 11. Qualitative findings are reported according to COREQ guidelines (S1 Checklist) [34]. The pilot trial was reported according to the Consolidated Standards of Reporting Trials (CONSORT) reporting guideline [35].

Results

Participant characteristics

Of 126 TB patients screened, 66 (52%) were enrolled in the study between January 2019 and December 2019. TB patients participants were randomized to three arms: daily SMS arm (N = 22), weekly SMS arm (N = 23) and the control arm (N = 21). Reasons for excluding participants are shown in Fig 1. All 45 social supporters identified by the TB patients in the two SMS arms were enrolled in the study.

Overall, the primary analysis considered 22 TB patients in the daily SMS arm, 20 TB patients in the weekly SMS arm, and 21 TB patients in the control arm, totaling to 63 TB patients. However, due to the three patients who died from the daily SMS arm and one who died and the other one who was lost to follow up (due to unreachable contact in the control arm), we only had 58 TB patients at study exit; 19 TB patients in the daily SMS arm, 20 in the weekly SMS arm, and 19 in the control arm. Of the 45 social supporters, three were disenrolled all from the weekly SMS arm after 3.5, 6.5, and 12.2 weeks respectively and their data was excluded for analysis because of disenrollment of their corresponding TB patients. Data from the three social supporters whose TB patients died (from the daily SMS arm) before completing the study were included for analysis. Overall, a total of 39 social supporters completed the study. As indicated in Table 1 below, of 63 TB patients, 32 (59%) were male, 53 (84%) had co-infection with HIV, and 47 (75%) had no regular income.

Table 1. Baseline demographic characteristics of participants.

Characteristic
TB patients (N = 63)
Social supporters (N = 42)
Stratification of TB patients by arm (n %
Daily SMS (n = 22) Weekly SMS
(n = 20)
Control
(n = 21)
Median age (IQR) 35 (28–44) 35.5 (28–44) 37.5 (32–54) 31 (25.5–41) 37 (30–43)
Gender
Male 37 (59%) 14 (33%) 14 (64%) 13 (65%) 10 (48%)
Female 26 (41%) 28 (66%) 8 (36%) 7 (35%) 11 (52%)
Marital status
Married 40 (64%) 29 (69%) 16 (73%) 14 (70%) 10 (48%)
Single 23 (36%) 13 (31%) 6 (27%) 6 (30%) 11 (52%)
Type of residence
Town 32 (51%) 22 (52%) 8 (36%) 11 (55%) 13 (62%)
Rural 31 (49%) 20 (48%) 14 (64%) 9 (45%) 8 (38%)
Level of education
None 1 (2%) 2 (4%) 0 (0%) 1 (5%) 0 (0%)
P1-P7 25 (40%) 15 (36%) 12 (55%) 5 (25%) 8 (38%)
>P7 37 (59%) 25 (60%) 10 (45%) 14 (70%) 13 (62%)
Income (fixed wages/ salary)
Yes 16 (25%) 10 (28%) 4 (18%) 5 (25%) 7 (33%)
No 47 (75%) 32 (72%) 18 (82%) 15 (75%) 14 (67%)
Heavy alcohol consumption a
Yes 7 (11%) 4 (10%) 2 (9%) 3 (15%) 2 (9%)
No 56 (89%) 38 (90%) 20 (91%) 17 (85%) 19 (91%)
TB stigma b
Median stigma (IQR) 2 (1–4) n/a 2 (1–4) 2 (1–5) 2 (1–3)
Enough social support
Yes 49 (78%) n/a 17 (77%) 17 (85%) 15 (71%)
No 14 (22%) 5 (23%) 3 (15%) 6 (29%)
Food Insecurity c
Severe Food Insecure 33 (52%) 17 (40%) 10 (45%) 11 (55%) 12 (57%)
Food secure 30 (48%) 25 (60%) 12 (55%) 9 (45%) 9 (43%)
Probable depression d
Yes 11 (18%) 2 (5%) 4 (18%) 3 (18%) 4 (19%)
No 52 (82%) 40 (95%) 18 (82%) 17 (82%) 17 (81%)
Asset index e
Lowest quartile 17 (27%) 11 (26%) 7 (32%) 5 (26%) 5 (24%)
25–100% quintiles 45 (73%) 31 (74%) 15 (68%) 14 (74%) 16 (76%)
Disclosed TB Status to anyone other than healthcare provider
Yes 52 (83%) n/a 18 (82%) 16 (80%) 18 (86%)
No 11 (17%) n/a 4 (18%) 4 (20%) 3 (14%)
HIV status
Negative 10 (16%) 26 (62%) 3 (14%) 3 (15%) 4 (19%)
Positive 53 (84%) 16 (38%) 19 (86%) 17 (85%) 17 (81%)
Social support relationship to the study participant
Spouse 22 (52%)
Family member 16 (38%)
Friend 4 (10%)

Notes: aScreening for heavy drinking was based on the AUDIT-C (Bush et al., 1998).

bTB stigma was measured using the internalized stigma scale (Kalichman et al 2009).

cFood insecurity was assessed using the nine item Household Food Insecurity Access Scale (HFIAS) by Coates, Swindale & Bilisnky (2006).

dDepression was measured using the measure proposed by Bolton, Wilk, and Ndogoni. (2004).

eAsset index was measured using the measure proposed by Filmer and Pritchett (2001).

Of the 42 social supporters, 28 (66%) were female, 16 (38%) had HIV, and 32 (22%) had no regular income.

Feasibility and acceptability

SMS reminders and notifications

All participants reported that SMS were easy to use (i.e., access and read). As indicated in Table 2 below, most of the daily [1913/2395 (80%)] and weekly SMS reminders [631/872 (72%)] were sent successfully. Also, most of the daily [1577/2395 (66%)] and weekly SMS notifications [740/872 (85%)], were sent successfully. Only 161/2395 (7%) of SMS were sent later due to a delay or absence of the corresponding signal. The sending of these SMS reminders occurred when the electronic adherence monitor had already been opened by the patients to take medication, but there was delay or absence of the corresponding signal due technical issues (such as poor network coverage). Most TB patients in the weekly SMS arm (n = 17; 89%) wished they had received daily SMS reminders to triggered SMS reminders. Responses from the open-ended question on reasons for the stated preferences revealed that daily SMS reminders matched well with daily pill taking and provided encouragement to TB patients daily, while triggered SMS texts were received after the scheduled pill taking time. The majority of the TB patients in the weekly arm (n = 16; 80%) preferred triggered SMS to weekly, reporting that weekly SMS reminders did not match well with daily pill taking. The majority of participants (n = 29; 74%) preferred personalized SMS reminders formulated by themselves (e.g. “How are you today”) to the default SMS formulated by the study (i.e. “This is your reminder”).

Table 2. Feasibility and acceptability of SMS reminders and notifications.
Feasibility and acceptability of SMS reminders to patients
N = 39 (i.e. 19 in the daily SMS arm and 20 in the weekly SMS arm who completed the study)
Issue Comments
Number of SMS reminders sent as planned • 1913/2395 (80%) of daily SMS
• 631/872 (72%) of weekly SMS
SMS reminders not delivered due to technical challenges (e.g., poor network coverage) • 132/2395 (13%) of daily SMS
• 183/872 (21%) of weekly SMS
Number of SMS sent later due to technical issues such as poor network • 161/2395 (7%) daily SMS
• 58/872 (7%) weekly
Number of triggered SMS sent • 113/1356 (8%)
• 296/1397 (21%)
Acceptability
Preference of SMS type/frequency*
Daily reminder versus triggered or weekly (N = 19)
Weekly reminders versus triggered or daily (N = 20)
17 (89%) from the daily arm preferred daily SMS reminders to triggered SMS reminders
None of the participants who received daily SMS wished they received weekly reminders.
16 (80%) from the weekly arm preferred triggered SMS reminders to weekly
17 (85%) who received weekly reminders wished they were receiving daily reminders
Default reminder
Personalized reminders
10 (26%) preferred default SMS text (i.e. “This is your reminder”)
29 (74%) preferred personalized SMS text—reminders formulated by TB patients themselves (e.g. “How are you today”, “Take care”, “Hello, have you had lunch”, “Football”, “How are you moving on”)
Feasibility and acceptability of notifications to social supporters N = 39 (i.e. 19 in the daily SMS arm and 20 in the weekly SMS arm
Number of SMS notifications sent as planned • 1577/2395 (66%) for daily SMS
• 740/872 (85%) for weekly SMS
SMS notifications not delivered due to technical challenges (e.g., poor network coverage)
• 639/2396 (27%) of daily notifications
• 45/872 (5%) of weekly notifications
Number of SMS notifications sent later due to technical issues such as poor network • 180/2395 (8%) of daily notifications
• 87/872 (10%) of weekly notifications

*Preference for SMS type/frequency was collected via patient questionnaires; all other data were collected from Wisepill device.

SMS notifications to social supporters

As indicated in Table 2 above, most of the daily [1577/2395 (66%)] and weekly SMS notifications [740/872 (85%)] were sent successfully. From the survey results, all social supporters (n = 39; 100%) reported providing some assistance to the participants at least once, after receiving SMS notifications. The assistance that involved some form of financial spending (such as providing money for transport to the clinic, buying food) was provided least often (n = 20; 51%) Non-monetary support such as emotional support was the most common support provided (n = 38; 97%). The majority of the social supporters from both the daily (n = 14; 74%) and weekly (n = 15; 75%) SMS arms respectively preferred triggered SMS notifications to daily or weekly SMS notifications. Social supporters (n = 24; 62%) reported improved relationships with their TB patients (e.g., frequent communication with each other) as a result of participating in this study. Many social supporters (n = 25; 64%) reported instances of failing to provide the assistance required by the TB patients, mainly due to lack of money (n = 15; 60%).

Real-time adherence monitor. As indicated in Table 3, all TB patients (n = 58; 100%) reported that using the real-time monitor: a) was useful in their TB medication adherence including being more useful than the pill sackets often used for TB medication; b) helped them take their medication in time/as prescribed; d) positively affected the way they felt about taking medicine; e) and made it easier for TB patients to take their medication. All participants also found the real-time monitor easy to use (e.g., opening and closing). Ten (18%) of TB patients reported ever taking pills from another source during the study period during travel or when they had not refilled the monitor, while 8 (14%) of TB patients reported opening the monitor without taking medication during refilling the monitor as well as accidental openings.

Table 3. Feasibility and acceptability of real-time adherence monitor.
(N = 58, i.e. 19 in the daily SMS arm, 20 in the weekly SMS arm, 19 in the control arm)
Feasibility issue Comments
Data loss* 342/9224 (3.7%) of data were lost because of technical issues with the adherence monitors.
Device malfunction* 2 (3%) out of 60 devices malfunctioned due to technical failures and were replaced.
Device battery changes*
Taking pills from another source
Reason(s) (n = 10)
•Was traveling
•Had not refilled the device
Openings without pill removal (n = 8)
•During refilling the monitor
•Opened accidently
Study staff replaced 4 batteries; poor mobile network resulted in repeated attempts to transmit the data which depleted the batteries before the anticipated battery lives.
10 (18%) of TB patients reported ever taking pills from another source during the study period.
7 (70%)
3 (30%)
4 (50%)
4 (50%)
Acceptability

Perceived usefulness
Perceived ease of use

58 (100%) of TB patients reported that the real-time monitor: a) was useful in their TB medication adherence; b) helped them take their medication in time/as prescribed; d) positively affected the way they felt about taking medicine; e) and made it easier for TB patients to take their medication.
58 (100%) of TB patients found the real-time monitor easy to open and close, and remember to get pills.
45 (78%) of TB patients found the real-time monitor easy to travel with.
Disclosure from the real-time monitor 3 (5%) of TB patients reported that the adherence monitor resulted in unwanted disclosure of their TB status

*Data about data loss, device malfunction, and battery changes were collected from Wisepill device. All other data were collected via patient questionnaires.

Acceptability of the technologies

As shown in Table 4 below, results from exit interviews indicated that receiving an SMS reminder and looking at the monitor reminded TB patients take their medications on time. Additionally, TB patients reported that being sent an SMS reminder and being monitored implied care and motivated medication taking. Also, TB patients reported receiving social support (e.g., reminders, counseling) from social supporters in response the SMS notifications received. Challenges reported by participants included possibility of TB status disclosure as a result of using the technologies, unreliable networks, and lack of money.

Table 4. Qualitative results demonstrating technology acceptability.
Theme Example quotation
Perceived usefulness
SMS reminders and real-time adherence monitor reminded participants to take their medications Whenever I would receive your SMS, immediately I would prepare and take my medication. ~Female, 33 years, TB patient, Daily SMS arm
R: I put the monitor near my bed, and when I look at it in the morning, I remember that one of the things I need to do in the morning is to take my drugs. ~ female, 33years, TB patient, Daily Arm A
Receiving SMS reminders and being monitored implied care I would feel good after receiving an SMS because I know that you are caring about my life and want me to get well. So, I tried to take my drugs well so that you do not think that you are minding about someone who does not mind about his own life. ~ Male, 41years, TB patient, Weekly SMS Arm.
Monitoring encourages medication adherence Because I knew you were monitoring the way I took my medication through the device, I made sure I was taking my medication because I did not want to disappoint people who cared about me. ~ Male 25 years, TB patient, Daily SMS Arm.
SMS notifications to social supporters enabled provision of social support Whenever he (social supporter) would receive your message, he would call me to check how I was feeling and remind me take medication, and I would take my medication immediately. ~ Male, 41 years, Weekly SMS Arm.
Whenever he sees your message, he tells me to open the device and swallow my drugs before the computer detects that I have not swallowed the drugs. Whenever he starts telling me this, he won’t stop until I have taken the drugs. ~ female, 56 years, TB patient, Daily SMS Arm
Challenges
Possibility of unintended TB status disclosure One time I went with it at my mother’s house, and when she saw the monitor, she asked what it was and I had to explain, and in the process she ended up knowing that I had TB. I think if I had not carried the device with me, she would not have known. ~Female, 33 years, TB patient, Daily SMS Arm.
Inability to address structural barriers to non-adherence When I got sick, I became too weak to continue working. So, sometimes when I have no food, and sometimes I have no money for transport to the clinic, thus, I still miss taking the medication even if I receive the SMS reminder ~ Female, 38 years, TB patient, Weekly SMS Arm B.

Medication adherence

Primary analysis

The median adherence over the 6-month study period was 96.1%, (IQR 84.8–98.0), 92.5% (IQR 80.6–96.3), and 92.2% (IQR 56.3–97.8) respectively in the daily SMS, weekly SMS, and control arms and was similar, within study arm, over the two study phases. In the univariable analysis, average adherence was 8.4% (-5.8, 22.5; p = 0.24) higher in the daily SMS arm than the control arm while that in the weekly SMS arm was 4.7 (-10.3, 19.8; p = 0.53) higher than that in control arm. In the multivariable analysis controlling for gender, food security, HIV status social support and TB disclosure, participants in the daily SMS arm had 9.9% (95% CI -4.8, 24.5; p = 0.18) higher adherence than participants in the control arm, while those in the weekly SMS arm had 6.3% (95% CI -8.7, 21.3; p = 0.40) higher adherence than those in the control arm. The results were similar when considering the secondary dataset. In both the univariate and multivariate analyses, the higher adherence observed was not statistically significant as indicated by the P values.

Discussion

Findings from this study show that real-time electronic monitoring and the use of SMS as reminders for TB patients and notifications for provision of social support were largely feasible and acceptable for TB medication adherence in southwestern Uganda. The pilot RCT revealed higher median adherence in the daily SMS and weekly SMS arms compared to the control, although the study was not powered for statistical significance when controlling for gender, food security, social support, stigma, and HIV status. These findings suggest preliminary evidence for clearly meaningful effect that should be considered for further evaluation in a fully powered larger trial.

The use of real-time adherence monitoring linked to SMS reminders to TB patients was feasible for supporting TB medication adherence in southwestern Uganda. All TB patients perceived the technologies to be easy to use. Most SMS reminders were sent as planned, demonstrating feasibility of this technology. The real-time medication monitors generally worked well; most of the adherence data was transferred as expected. Although no other studies have reported the feasibility of real-time adherence monitoring linked to SMS reminders for TB medication (studies such as the ASCENT trial, ClinicalTrials.gov number, NCT02574455 will be forthcoming), these technologies have been similarly reported to be feasible for monitoring ART adherence [17]. Despite the general feasibility of the technologies in the current study, poor mobile networks, not using the technology appropriately, and lack of money for transport to the clinic could limit the impact of the intervention. Notably, cellphone network is rapidly expanding in Uganda [36], and there is widespread cellphone adoption including among TB patients [37], suggesting these technical challenges may improve with time. “With 2G networks reaching nearly the entire population in Uganda, and with mobile broadband networks (3G/4G) covering more than 80% of the country [38], poor network is not a significant challenge. Although reported by few participants, opening the monitor without taking medication or taking medication from other sources could limit the accuracy of adherence monitoring. Some of this bias can be accounted for in analysis (e.g. excluding more openings per day than would be expected).

The use of social support notifications to social supporters was feasible—most notifications were sent as planned, and all social supporters reported assisting the participants (e.g. transport to the clinic, money for buying food and drinks, counseling) at least once after receiving SMS notifications. Social support (such as food supplements, and economic support) delivered through face-to-face approaches improved TB treatment completion in various settings including low resource settings such as Nepal, Burkina Faso, and Haiti [32]. However, the impact of SMS notifications could be constrained by the reported lack of financial resources to support TB patients. Complementing the SMS notification intervention with interventions to boost the economic status [39] of social supporters (e.g. through income generating activities such as farming) may improve their capacity to provide the support needed by the patients.

The use of real-time adherence monitoring linked to SMS reminders to TB patients and notifications to social supporters was acceptable for supporting TB medication adherence in this setting. All TB patients perceived the technologies to be useful in supporting TB medication adherence. Receiving SMS reminders and being monitored reminded TB patients to take their medication on time, thus, addressing the challenge of forgetfulness. This function is especially important for TB patients with busy schedules or those inexperienced with regular medication. Additionally, receiving SMS and being monitored with a real-time monitor were perceived as being “cared for”. This perception can encourage TB patients to take medication in order to cooperate with those who gave them the intervention while at the same time taking care of their own lives. Notably, the use of these technologies to support ART medication adherence was reported to be acceptable among people living with HIV in the same setting [17].

Overall, our findings indicate that real-time adherence monitoring linked to SMS reminders to TB patients and notifications to social supporters is feasible and acceptable for supporting TB drug administration. This is specifically critical in settings like Uganda where the implementation of DOT has been abandoned mainly due to the financial burden it places on the TB patients (in the form of transport to the clinic for drug administration), as well as time demands on healthcare workers (who have to physically watch TB patients take their medication amidst other competing demands). This technology can keep TB patients connected with healthcare supporters, which can potentially minimize the challenge of social isolation that is often associated with TB.

Our study found that SMS reminders may improve TB medication adherence. Compared to weekly or triggered SMS, TB patients found daily reminders matching well with their daily pill taking and perceived them as daily encouragements to take their medications. The prior study in the same setting showed that daily SMS reminders integrated with real-time monitoring can improve ART adherence [18]. High quality studies utilizing SMS reminders (not linked to real-time adherence monitoring) to support TB medication report mixed results. A recent systematic review of 14 randomized controlled trials and quasi-experimental studies done prior to 2019 reported essentially no difference in TB treatment success (i.e. pooled estimate of 87% with SMS vs 85% in the control group) [40]. In another recent systematic review of 16 randomized controlled trials that utilized digital health technologies to support TB medication adherence, only 2 of the 8 studies that utilized interactive SMS reminders and educational SMS texts reported positive benefits of using this technology in reducing medication adherence defaults and increasing cure rate in China [41] and treatment adherence and cure rate in Argentina [42]. Compared to our SMS reminder system that was one-way, automatic and linked to a real-time technology, the study in Argentina was more interactive and had a common feature of providing a sense of regular support. The remainder of the SMS reminder studies (not linked to a real-time technology) found no effect of SMS reminders on TB medication adherence compared to the standard of care in United States, Spain, Hong Kong, and South Africa [4347]. British Columbia Canada [44], Sudan [45], Pakistan [48], and Cameroon [49]. In the same review, the use of real-time adherence monitors integrated with medication reminders resulted in fewer missed doses compared to real-time adherence monitors without reminders in China [19], while real-time adherence monitors without reminders reduced TB treatment defaults in Haiti [50]. The variable results among studies of SMS reminders highlight the importance of understanding how the technology is used and perceived. The causes of the differences in findings are unclear but might relate to context, culture, degree of technology exposure, TB patients involvement in technology development, fidelity of technology use, varying measures of adherence, access to social support, and other factors such as depression, and lack of transport to the clinic.

The acceptability of the technologies can be limited by the possibility of unintended TB status disclosure (e.g., when someone sees the SMS or monitor) which might result into stigma and discrimination. Using messages that are not easily linked with TB as preferred in this study can reduce the possibility of SMS-enabled unintended status disclosure. It should however be noted that technology-enabled disease status disclosure is not always unwanted; for instance, participants living with HIV in the same setting had previously reported using the monitor to intentionally disclose their HIV status mainly to enable them get social support [51]. For TB patients who would want to keep their status private, the monitor-led unwanted status disclosure could be minimized by redesigning it to better meet the needs of TB patients (e.g., making the monitor more portable and discreet). Additionally, interventions that reduce stigma can be incorporated.

In the current study, many social supporters reported improved relationship with TB patients as a result of using the SMS notifications. Social supporters might have felt more obliged to be there for TB patients after having been identified (by TB patients themselves) as their helpers (who should receive notifications), in order not to disappoint them. TB patients might have felt the need to meet the expectations (i.e., adherence) of social supporters to not to undermine the support provided and to keep getting the support [52]. This finding is in contrast to that reported in a related intervention for supporting ART adherence in the same setting, in which some conflicts arose as a result of mismatch of expectations between TB patients and their social supporters [25] and lack of clear benefits of social support [18]. Formative results from the current study highlighted the possibility of misunderstandings between social supporters and TB patients as a result of the frequent receipt of SMS notifications which may be perceived as lack of commitment to taking medication [53]. The possibility of such misunderstandings was managed through orientation.

This study has some limitations. From qualitative work, we found out the real-time monitor alone can motivate TB patients to take medication. Therefore, using the real-time monitor in the control arm could have had its own intervention effect, which might have affected the detection of intervention effects in other study arms. Although the use of the real-time adherence monitor may be more accurate than traditional approaches to adherence monitoring (such as self-report and clinic-based pill counts), its non-use (e.g., taking drugs from other sources during travel) and/or inappropriate use (e.g., opening it without taking medication) might have affected the accuracy of adherence estimations of a few TB patients across study arms. Also, for this pilot study, rather than intention to treat analysis, we used per protocol analysis that involved excluding TB patients who voluntarily withdrew from the study or declined to use the adherence monitor. Being a pilot study, the small sample size involved limits results generalizability. Lastly, since participants self-reported their perceptions about the intervention, qualitative results (and some self-reported quantitative aspects) could be vulnerable to social desirability bias especially since participants knew that they were reporting on the intervention given to them by the same researchers collecting data from them.

To the best of our knowledge, this is the first study to investigate the use of real-time adherence monitoring linked to SMS reminders to TB patients and notifications to social supporters among TB patients. Real-time monitoring creates the potential for intervening prior to the development of treatment failure and/or drug resistance. Our multiple approaches to the use of SMS (i.e. daily, weekly, triggered) made it possible to identify TB patients’ preferences and highlight the usefulness of these approaches.

In summary, we found that real-time adherence monitoring linked to daily SMS reminders and notifications followed by triggered SMS reminders and notification is generally feasible. SMS were sent and received as planned, and data from the monitor was transferred as expected, most of the time. The technology was acceptable and feasible in a resource limited setting. The intervention appeared to improve TB adherence, though the difference in study arms was not significant; importantly, this study was not powered for differences in medication adherence. Larger studies are needed to determine the larger-scale feasibility, acceptability, and impact on TB treatment adherence and clinical outcomes. Integrating economic support to the intervention could empower social supporters to meet the financial needs of TB patients, which they would otherwise not be able to meet; such work is ongoing (NCT05656287). Future work should also analyze the cost of the technology to inform potential scalability.

Supporting information

S1 Checklist. Reporting checklist for randomised trial.

(DOCX)

S2 Checklist

(DOCX)

S1 Appendix. Univariable and multivariate analysis of adherence across arms.

(DOCX)

S1 File. Trial protocol.

(DOC)

S1 Text. Questionnaire packet—study title: Real time tuberculosis medication adherence intervention in rural southwestern Uganda.

(DOC)

Acknowledgments

The authors would like to acknowledge the contributions of Wisepill Technologies and study participants.

Data Availability

Data from this study contain sensitive patient information. Also, sharing this data breach the compliance with the protocol approved our research ethics board. However, de-identified individual data that supports the results will be shared following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Committee (REC), as applicable, and executes a data use/sharing agreement with Mbarara University of Science and Technology (MUST). Researchers may apply for data access by contacting the corresponding author or the MUST Research Ethics Committee at sec@rec.must.ac.ug.

Funding Statement

Funding: This work was supported by the Fogarty International Center of the National Institutes of Health (K43TW010388 to AM). The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the Fogarty International Center of the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Authors AM, AMT and WT received salaries from the Fogarty International Center of the National Institutes of Health (K43TW010388 to AM).

References

  • 1.Yoeli E, Rathauser J, Rand D. The resurgence of tuberculosis is behavioral, not medical. Nudges can fix it. 2019. 2019 [cited 2022 19th April]. Available from: https://www.statnews.com/2019/10/25/tuberculosis-behavior-text-based-nudges/. [Google Scholar]
  • 2.WHO. World Health Organization. Global tuberculosis control: WHO report 2021. 2021. [Google Scholar]
  • 3.WHO. Tuberculosis profile: Uganda. World Health Organization; 2020. [cited 2022 19th April]. Available from: https://worldhealthorg.shinyapps.io/tb_profiles/?_inputs_&entity_type=%22country%22&lan=%22EN%22&iso2=%22UG%22. [Google Scholar]
  • 4.MOH. National Tuberculosis and Leprosy Control Programme. Revised National Strategic Plan 2015/16–2019/20. 2017. [Google Scholar]
  • 5.Musiimenta A, Tumuhimbise W, Atukunda EC, Mugaba AT, Muzoora C, Armstrong-Hough M, et al. Mobile health technologies may be acceptable tools for providing social support to tuberculosis patients in rural Uganda: A parallel mixed-method study. Tuberculosis research and treatment. 2020;2020. doi: 10.1155/2020/7401045 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.MOH. The Uganda Tuberculosis Communication Strategy. 2010. Ministry of Health. 2010. [Google Scholar]
  • 7.Nglazi MD, Bekker L-G, Wood R, Hussey GD, Wiysonge CS. Mobile phone text messaging for promoting adherence to anti-tuberculosis treatment: a systematic review. BMC infectious diseases. 2013;13(1):1–16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Horsburgh CR Jr, Barry CE III, Lange C. Treatment of tuberculosis. New England Journal of Medicine. 2015;373(22):2149–60. doi: 10.1056/NEJMra1413919 [DOI] [PubMed] [Google Scholar]
  • 9.Adane AA, Alene KA, Koye DN, Zeleke BM. Non-adherence to anti-tuberculosis treatment and determinant factors among patients with tuberculosis in northwest Ethiopia. PloS one. 2013;8(11). doi: 10.1371/journal.pone.0078791 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.WHO. World Health Organization. Global tuberculosis control: WHO report 2000. 2000. [Google Scholar]
  • 11.Organization WH. What is DOTS?: a guide to understanding the WHO-recommended TB control strategy known as DOTS. World Health Organization, 1999. [Google Scholar]
  • 12.O’Donnell MR, Daftary A, Frick M, Hirsch-Moverman Y, Amico KR, Senthilingam M, et al. Re-inventing adherence: toward a patient-centered model of care for drug-resistant tuberculosis and HIV. The International Journal of Tuberculosis and Lung Disease. 2016;20(4):430–4. doi: 10.5588/ijtld.15.0360 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Tanimura T, Jaramillo E, Weil D, Raviglione M, Lönnroth K. Financial burden for tuberculosis patients in low-and middle-income countries: a systematic review. European Respiratory Journal. 2014;43(6):1763–75. doi: 10.1183/09031936.00193413 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Sagbakken M, Frich JC, Bjune GA, Porter JD. Ethical aspects of directly observed treatment for tuberculosis: a cross-cultural comparison. BMC medical ethics. 2013;14(1):1–10. doi: 10.1186/1472-6939-14-25 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Pasipanodya JG, Gumbo T. A meta-analysis of self-administered vs directly observed therapy effect on microbiologic failure, relapse, and acquired drug resistance in tuberculosis patients. Clinical Infectious Diseases. 2013;57(1):21–31. doi: 10.1093/cid/cit167 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.WHO. Guidelines for treatment of drug-susceptible tuberculosis and patient care [Online]. World Health Organization. 2017. [cited 2022 19th April]. Available from: https://apps.who.int/iris/bitstream/handle/10665/255052/9789241550000-. [Google Scholar]
  • 17.Musiimenta A, Atukunda EC, Tumuhimbise W, Pisarski EE, Tam M, Wyatt MA, et al. Acceptability and feasibility of real-time antiretroviral therapy adherence interventions in rural Uganda: mixed-method pilot randomized controlled trial. JMIR mHealth and uHealth. 2018;6(5):e9031. doi: 10.2196/mhealth.9031 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Haberer JE, Musiimenta A, Atukunda EC, Musinguzi N, Wyatt MA, Ware NC, et al. Short message service (SMS) reminders and real-time adherence monitoring improve antiretroviral therapy adherence in rural Uganda. AIDS (London, England). 2016;30(8):1295. doi: 10.1097/QAD.0000000000001021 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Liu X, Lewis JJ, Zhang H, Lu W, Zhang S, Zheng G, et al. Effectiveness of electronic reminders to improve medication adherence in tuberculosis patients: a cluster-randomised trial. PLoS medicine. 2015;12(9):e1001876. doi: 10.1371/journal.pmed.1001876 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Ngwatu BK, Nsengiyumva NP, Oxlade O, Mappin-Kasirer B, Nguyen NL, Jaramillo E, et al. The impact of digital health technologies on tuberculosis treatment: a systematic review. European Respiratory Journal. 2018;51(1). doi: 10.1183/13993003.01596-2017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Ridho A, Alfian SD, van Boven JF, Levita J, Yalcin EA, Le L, et al. Digital Health Technologies to Improve Medication Adherence and Treatment Outcomes in Patients with Tuberculosis: Systematic Review of Randomized Controlled Trials. Journal of medical Internet research. 2022;24(2):e33062. doi: 10.2196/33062 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Iribarren SJ, Milligan H, Chirico C, Goodwin K, Schnall R, Telles H, et al. Patient-centered mobile tuberculosis treatment support tools (TB-TSTs) to improve treatment adherence: A pilot randomized controlled trial exploring feasibility, acceptability and refinement needs. The Lancet Regional Health—Americas. 2022;13. doi: 10.1016/j.lana.2022.100291 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Boutilier JJ, Yoeli E, Rathauser J, Owiti P, Subbaraman R, Jónasson JO. Can digital adherence technologies reduce inequity in tuberculosis treatment success? Evidence from a randomised controlled trial. BMJ Global Health. 2022;7(12):e010512. doi: 10.1136/bmjgh-2022-010512 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Musiimenta A, Tumuhimbise W, Mugaba AT, Muzoora C, Armstrong-Hough M, Bangsberg D, et al. Digital monitoring technologies could enhance tuberculosis medication adherence in Uganda: Mixed methods study. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases. 2019;17:100119. doi: 10.1016/j.jctube.2019.100119 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Atukunda EC, Musiimenta A, Musinguzi N, Wyatt MA, Ashaba J, Ware NC, et al. Understanding patterns of social support and their relationship to an ART adherence intervention among adults in rural Southwestern Uganda. AIDS and Behavior. 2017;21(2):428–40. doi: 10.1007/s10461-016-1559-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Bolton P, Wilk CM, Ndogoni L. Assessment of depression prevalence in rural Uganda using symptom and function criteria. Social psychiatry and psychiatric epidemiology. 2004;39(6):442. doi: 10.1007/s00127-004-0763-3 [DOI] [PubMed] [Google Scholar]
  • 27.Tsai AC, Bangsberg DR, Frongillo EA, Hunt PW, Muzoora C, Martin JN, et al. Food insecurity, depression and the modifying role of social support among people living with HIV/AIDS in rural Uganda. Social science & medicine. 2012;74(12). doi: 10.1016/j.socscimed.2012.02.033 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA, Project ACQI. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Archives of internal medicine. 1998;158(16):1789–95. [DOI] [PubMed] [Google Scholar]
  • 29.Broadhead W, Gehlbach SH, De Gruy FV, Kaplan BH. The Duke-UNC Functional Social Support Questionnaire: Measurement of social support in family medicine patients. Medical care. 1988:709–23. [DOI] [PubMed] [Google Scholar]
  • 30.Kalichman SC, Simbayi LC, Cloete A, Mthembu PP, Mkhonta RN, Ginindza T. Measuring AIDS stigmas in people living with HIV/AIDS: the Internalized AIDS-Related Stigma Scale. AIDS care. 2009;21(1):87–93. doi: 10.1080/09540120802032627 [DOI] [PubMed] [Google Scholar]
  • 31.Venkatesh V, Morris MG, Davis GB, Davis FD. User acceptance of information technology: Toward a unified view. MIS quarterly. 2003:425–78. [Google Scholar]
  • 32.Van Hoon R, Kievit W, Booth A, Lysdahl K, Refolo P, Sacchini D, et al. The retrieval and critical appraisal of literature on patient preferences for treatment outcomes. 2016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qualitative Health Research,. 2005;15(9):1277–88. doi: 10.1177/1049732305276687 [DOI] [PubMed] [Google Scholar]
  • 34.Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. International journal for quality in health care. 2007;19(6):349–57. doi: 10.1093/intqhc/mzm042 [DOI] [PubMed] [Google Scholar]
  • 35.Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. Journal of Pharmacology and pharmacotherapeutics. 2010;1(2):100–7. doi: 10.4103/0976-500X.72352 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.ITU. International Telecommunication Union. Key global telecom indicators for the world telecommunication service sector 2016. [cited 2022 9th December]. Available from: http://www.itu.int/en/ITU-D/Statistics/Documents/statistics/2016/ITU_Key_2005-2016_ICT_data.xls. [Google Scholar]
  • 37.Ggita JM, Ojok C, Meyer AJ, Farr K, Shete PB, Ochom E, et al. Patterns of usage and preferences of users for tuberculosis-related text messages and voice calls in Uganda. The International Journal of Tuberculosis and Lung Disease. 2018;22(5):530–6. doi: 10.5588/ijtld.17.0521 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.GSMA. The Mobile Economy 2021. 2021. [Google Scholar]
  • 39.Weiser SD, Bukusi EA, Steinfeld RL, Frongillo EA, Elly W, Dworkin SL, et al. Shamba maisha: Randomized controlled trial of an agricultural and finance intervention to improve HIV health outcomes in Kenya. AIDS (London, England). 2015;29(14):1889. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Gashu KD, Gelaye KA, Mekonnen ZA, Lester R, Tilahun B. Does phone messaging improves tuberculosis treatment success? A systematic review and meta-analysis. BMC infectious diseases. 2020;20(1):1–13. doi: 10.1186/s12879-020-4765-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Fang X-H, Guan S-Y, Tang L, Tao F-B, Zou Z, Wang J-X, et al. Effect of short message service on management of pulmonary tuberculosis patients in Anhui Province, China: a prospective, randomized, controlled study. Medical science monitor: international medical journal of experimental and clinical research. 2017;23:2465. doi: 10.12659/msm.904957 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Iribarren S, Beck S, Pearce PF, Chirico C, Etchevarria M, Cardinale D, et al. TextTB: a mixed method pilot study evaluating acceptance, feasibility, and exploring initial efficacy of a text messaging intervention to support TB treatment adherence. Tuberculosis research and treatment. 2013;2013. doi: 10.1155/2013/349394 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Belknap R, Holland D, Feng P-J, Millet J-P, Caylà JA, Martinson NA, et al. Self-administered versus directly observed once-weekly isoniazid and rifapentine treatment of latent tuberculosis infection: a randomized trial. Annals of internal medicine. 2017;167(10):689–97. doi: 10.7326/M17-1150 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Johnston JC, van der Kop ML, Smillie K, Ogilvie G, Marra F, Sadatsafavi M, et al. The effect of text messaging on latent tuberculosis treatment adherence: a randomised controlled trial. European Respiratory Journal. 2018;51(2). doi: 10.1183/13993003.01488-2017 [DOI] [PubMed] [Google Scholar]
  • 45.Ali AOA, Prins MH. Mobile health to improve adherence to tuberculosis treatment in Khartoum state, Sudan. Journal of Public Health in Africa. 2019;10(2). doi: 10.4081/jphia.2019.1101 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Mohammed S, Glennerster R, Khan AJ. Impact of a daily SMS medication reminder system on tuberculosis treatment outcomes: a randomized controlled trial. PloS one. 2016;11(11). doi: 10.1371/journal.pone.0162944 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Bediang G, Stoll B, Elia N, Abena J-L, Geissbuhler A. SMS reminders to improve adherence and cure of tuberculosis patients in Cameroon (TB-SMS Cameroon): a randomised controlled trial. BMC public health. 2018;18:1–14. doi: 10.1186/s12889-018-5502-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Mohammed S, Glennerster R, Khan AJ. Impact of a daily SMS medication reminder system on tuberculosis treatment outcomes: a randomized controlled trial. PloS one. 2016;11(11):e0162944. doi: 10.1371/journal.pone.0162944 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Bediang G, Stoll B, Elia N, Abena J-L, Geissbuhler A. SMS reminders to improve adherence and cure of tuberculosis patients in Cameroon (TB-SMS Cameroon): a randomised controlled trial. BMC Public Health. 2018;18(1):1–14. doi: 10.1186/s12889-018-5502-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Moulding T S, Caymittes M. Managing medication compliance of tuberculosis patients in Haiti with medication monitors. The International Journal of Tuberculosis and Lung Disease. 2002;6(4):313–9. [PubMed] [Google Scholar]
  • 51.Musiimenta A, Campbell JI, Tumuhimbise W, Burns B, Atukunda EC, Eyal N, et al. Electronic Adherence Monitoring May Facilitate Intentional HIV Status Disclosure Among People Living with HIV in Rural Southwestern Uganda. AIDS and Behavior. 2021;25(7):2131–8. doi: 10.1007/s10461-020-03143-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Ware NC, Idoko J, Kaaya S, Biraro IA, Wyatt MA, Agbaji O, et al. Explaining adherence success in sub-Saharan Africa: an ethnographic study. PLoS medicine. 2009;6(1):e1000011. doi: 10.1371/journal.pmed.1000011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Musiimenta A, Tumuhimbise W, Mugaba AT, Muzoora C, Armstrong-Hough M, Bangsberg D, et al. Digital monitoring technologies could enhance tuberculosis medication adherence in Uganda: Mixed methods study. Journal of clinical tuberculosis and other mycobacterial diseases. 2019;17:100119. doi: 10.1016/j.jctube.2019.100119 [DOI] [PMC free article] [PubMed] [Google Scholar]
PLOS Glob Public Health. doi: 10.1371/journal.pgph.0001813.r001

Decision Letter 0

Lucy Chimoyi

Transfer Alert

This paper was transferred from another journal. As a result, its full editorial history (including decision letters, peer reviews and author responses) may not be present.

25 Apr 2023

PGPH-D-23-00372

The Feasibility, Acceptability, and Preliminary Impact of Real-Time Monitors and SMS on Tuberculosis Medication Adherence: Findings from a Pilot Randomized Controlled Trial

PLOS Global Public Health

Dear Dr. Musiimenta,

Thank you for submitting your manuscript to PLOS Global Public Health. After careful consideration, we feel that it has merit but does not fully meet PLOS Global Public Health’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by 08 May 2023. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at globalpubhealth@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pgph/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

We look forward to receiving your revised manuscript.

Kind regards,

Dr. Lucy Chimoyi, PhD

Academic Editor

PLOS Global Public Health

Journal Requirements:

1. Please provide separate figure files in .tif or .eps format only and remove any figures embedded in your manuscript file. Please also ensure that all files are under our size limit of 10MB.

For more information about figure files please see our guidelines:

https://journals.plos.org/globalpublichealth/s/figures 

https://journals.plos.org/globalpublichealth/s/figures#loc-file-requirement

2. Please amend your detailed Financial Disclosure statement. This is published with the article. It must therefore be completed in full sentences and contain the exact wording you wish to be published.

a. State the initials, alongside each funding source, of each author to receive each grant.

b. State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

c. If any authors received a salary from any of your funders, please state which authors and which funders.

If you did not receive any funding for this study, please simply state: “The authors received no specific funding for this work.”

3. We have noticed that you have uploaded Supporting Information files, but you have not included a list of legends. Please add a full list of legends for your Supporting Information files after the references list.

4. In the online submission form, you indicated that "The datasets analysed during the current study are available from the corresponding author on reasonable request". All PLOS journals now require all data underlying the findings described in their manuscript to be freely available to other researchers, either 1. In a public repository, 2. Within the manuscript itself, or 3. Uploaded as supplementary information.

This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If your data cannot be made publicly available for ethical or legal reasons (e.g., public availability would compromise patient privacy), please explain your reasons by return email and your exemption request will be escalated to the editor for approval. Your exemption request will be handled independently and will not hold up the peer review process, but will need to be resolved should your manuscript be accepted for publication. One of the Editorial team will then be in touch if there are any issues.

Additional Editor Comments (if provided):

1.The qualitative data collection tools were developed using the UTAUT. I am assuming that the analysis and presentation of  results followed this theory. However, this is not clear from Table 4. Include the theory used as part of the caption. 

2. It is advisable for authors to include in their title that this manuscript followed a mixed-methods approach.

3. A sub-section on outcome measures in the methods section should be included and all outcome measures defined (feasibility, acceptability and adherence).

4.From this work, do you think that poor network coverage is a problem or a limitation? This has been mentioned in the results, but authors have not discussed its implication. Is it something that implementers need to be concerned about?

5. Thank you for including the CONSORT checklist, also include the COREQ checklist

6. Was saturation determined during analysis of the qualitative data?

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does this manuscript meet PLOS Global Public Health’s publication criteria? Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe methodologically and ethically rigorous research with conclusions that are appropriately drawn based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS Global Public Health does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This article reports the feasibility and acceptability of a piloted TB adherence support strategy that combines a medication reminder box and SMS reminders to both patients and supporters. The study is a valuable addition to the TB digital adherence technology literature, but there are several aspects where I believe that there is incomplete reporting or a lack of transparency/clarity in the methods and results.

1) The second paragraph of the introduction refers to DOTS, which I find confusing because of the way this acronym has been used by WHO. The authors are discussing the practice of directly observed therapy (commonly abbreviated DOT), and I agree with everything they say about its shortcomings. However, the authors use the abbreviation DOTS (with the terminal S), which is generally used to refer to the old WHO DOTS Strategy. This strategy was included much more than DOT. It had five components - government commitment, a reliance on smear microscopy, directly observed short-course treatment, uninterrupted drug supply, and standardized reporting; even the third component (which corresponds to the phrase “directly observed therapy – short course” mentioned by the authors) encompassed not only the practice of DOT but the specific regimens that were recommended at the time. I think the authors should make it clear that they are talking about the practice of DOT, not the DOTS Strategy. This confusion could be resolved by simply defining the phrase “directly observed therapy (DOT)” in the first sentence of the paragraph, and using the abbreviation DOT rather than DOTS throughout.

2) In the statistical analysis section, I am a little confused by the use of the term “censoring.” My understanding of the term censoring in statistics is that it is used (usually for survival analysis) when partial information is known about the outcome, specifically that the event of interest has not yet occurred by a certain point, but that it will happen in the future. If I am understanding the analysis correctly, the authors did not use a survival analysis – I believe they used a linear regression with adherence as a continuous outcome. There are various periods of time that are excluded from the adherence calculation (e.g. time after death), but I do not think that this is censoring because the information about the outcome is not in doubt (participants could not have been adherent after death), and the regression model is not treating it as such. Maybe it would be clearer to just say that these days were excluded from the adherence calculation (i.e. excluded from both numerator and denominator)?

3) A definition of unnecessary SMS (reported in Table 2) and how it was determined should be included in the methods.

4) I suggest that the authors include the questionnaire as a supplementary file. It is unclear how some of the information in Tables 2 and 3 and the text was elicited (specifically the sections “SMS reminders and notifications”, “SMS notifications to social supporters”, and “real-time adherence monitor”). For example, how were patients asked about their preference for daily/weekly versus triggered SMS reminders given that they presumably received both? Do the responses mean that they would have wanted *only* the triggered reminders? How was ease of use assessed – a binary answer of “easy” or “difficult” or a Likert scale? Was fear of disclosure specifically asked about, or did 5% report this unintended consequence in the open-ended part of the questionnaire? What other forms of support could have been reported by treatment supporters.

5) Tables 2 and 3 mix indicators that were collected via the device, as well as things that I assume the authors could only know by asking the patient, and things that may have been recorded through the study teams’ field notes. This makes it a little confusing to evaluate, and it makes me wonder why these particular indicators are being reported in the tables. One way to improve transparency would be to add a column or footnotes to the table indicating the source of each data element. Another would be to include the questionnaire as supplementary information as noted above.

6) How many subjects participated in interviews? Did the interviewees know that the interviewers were representatives of the study that provided the monitors (raising the possibility of social acceptability bias in responses)? (I am not going to go down the COREQ checklist and raise every point that is not included in the methods, but I think that these two points are particularly important for judging validity).

7) In the qualitative interviews, were there minority opinions of participants who contradicted the general themes included under “perceived usefulness”? For instance, was there anyone who said that the medication reminder was annoying and that they would have remembered to take their meds anyway since they are used to taking daily ART? The qualitative results reported are rather scanty, and all but one of the themes reported about the technology itself are positive. This raises the concern that negative or ambivalent opinions are not being reported to make a case for acceptability.

8) The second paragraph of the discussion is confusing in that the first sentence claims, “the use of social support notifications to social supporters was feasible,” while the third sentence says “the feasibility of SMS notifications to social supporters in our study was limited.” The following sentences then talk about the need to improve feasibility. I think that the authors are either mixing the discussion of feasibility of two different things, or, starting with the third sentence, they are actually making a different point that is not about feasibility. The first sentence is clearly talking about the feasibility of delivering SMS notifications to social supporters. The remaining sentences are discussing whether these notifications are likely to have an impact given the limited ability of social supporters to overcome socioeconomic barriers. To me, this is a different point that is not about feasibility. However, the authors may be conceptualizing the point as a broader discussion about the feasibility of a hypothetical social support intervention that could utilize the SMS messages – not the actual intervention they piloted. I am fine with either conceptualization, but it has to be clear *what* is feasible or not.

Minor:

Line 342 reports that “participants who had disclosed their status” had lower adherence. What statis was being disclosed and to whom?

Line 443 – I think the authors mean discreet, not discrete

Reviewer #2: Thank you authors for this informative manuscript. Kindly find herewith some suggestions and questions that would help improve this work.

Line 167 - 168 ? -- What criteria was used by the Wisepill to determine acceptability and feasibility?

Line 263 "Overall, a total of 39 social supporters completed the study"

line 266 "Of the 42 social supporters"

Line 295 "All social supporters (n = 39; 100%)

Please clarify the correct number of social supporters analyzed.

line 259 - "..totaling to 63 PLTB"

Line 269 Table 1 - baseline demographics characteristics shows (N=63)

Line 307 -- "All PLTB completing the study (n=58; 100%)"

Please clarify the correct number of PLTB analyzed.

Line 315; Table 3, Reason(s) (n = 10)

However, the corresponding total number of the participants in the three reasons is greater than 10 i.e. (7+3+8 = 18)

Deeper analysis based on stratifying the TB treatment phases; intensive phase (2 months) and continuation phase (4-6 months) based on the frequency of reminders could further inform the non-adherence

During the qualitative data analysis, did any patient raise the issue of SMS reminders fatigue due to the daily frequency of incoming messages as reported in other studies? JAMA Intern Med. 2016;176(3):340-349. doi:10.1001/jamainternmed.2015.7667

Overall grammatical corrections to improve readability

Reviewer #3: Congratulations to this team for a fantastic study and a comprehensive and interesting evaluation of real-time adherence monitoring. The combination of qualitative data provides a nice overview of the benefits and potential drawbacks of this approach. Below I list a number of issues, nearly all minor, that should be clarified.

Author affiliations – no one is assigned 5 or 6.

Abstract: please specify primary outcomes. Was adherence a primary outcome?

Abstract: Please add confidence intervals around adherence percentages – remove reference to “may have improved adherence” as there is little evidence cited in the abstract for this. Alternatively cite the adjusted adherence findings with confidence intervals and could leave this in. See my note at the end regarding statistical significance.

Throughout the paper there seems to be a conflation of DOTS (the broader 5 tenet strategy) and DOT (directly observed treatment), which is an element of DOTS. To my read, DOTS is used in places where DOT, but not DOTS, would be appropriate.

Line 93 – minor typo “bn”

Page 5 refers to formative findings from the current study and then a formative study. Which is correct? Or are these references to two different studies?

Line 135 p6: Change “cater for” to “account for”

P6, line 138 – what does it mean to recruit them at random? Was this a convenience sample? If not, explain the systematic for recruitment

Line 143 – Explain how access to cellular network was assessed.

Not clear how purposive sampling fits in to the design. To whom does this apply? People with TB? Supporters? Both?

Could a patient participate if they did not have a supporter?

How often and at what frequency were SMS reminders sent to supporters? Was it the same as for the PLTB?

Primary outcomes are defined as adherence but as the authors note, there was insufficient power for these outcomes. Were these really the primary outcomes or were the primary outcomes feasibility and acceptability?

Line 193 – what do the authors mean by non-responsiveness?

When was the data censored in patients with LTFU? At the end of the two months without treatment or the beginning of those first two months?

Line 223 – perhaps “secondary data analysis” instead of “dataset”?

Why were HIV and social support, versus other variables, considered a priori confounders? Especially in the context of a trial?

Line 263 – 39 of 45 completed the study but the text only explains that 3 of the 45 were excluded. What happened to the other 3?

Nearly 25% of messages were not received – this demonstrates feasibility and room for improvement; worth highlighting this in the discussion

Table 1 is very nice.

Table 2 is also nice, but it would be useful to have the percentage of daily, weekly and triggered messages received rather than the percentage of messages received that were daily, weekly, triggered. Same with messages not sent.

In tables – use Severely Food Insecure or Severe Food Insecurity

Possible to differentiate between messages not sent and those that were delayed – it seems like this is an important distinction.

Could provide more info on unnecessary messages

Lines 297-299 is difficult to understand – could be reworded for clarity

Lines 302 – 305 could be further explained.

Table 3 - Opening the monitor without taking pills is in the wrong place I think

Qualitative table: Lack of money – is this the right title for this theme? It doesn’t relate to the technology. A more suitable title might be “inability to address structural causes of non-adherence” or something along those lines. Adherence monitoring can overcome forgetfulness and perhaps mitigate others, but is unlikely to triumph over extreme poverty.

Lines 333/3 – please add labels to the numbers in parentheses. Are these confidence intervals? Ranges?

There is an adjusted analysis in lines 335/6. The results of an equivalent, unadjusted analysis should precede the adjusted analysis.

Disclosure is adjusted for but not included in the table 1.

Suggest removing the findings related to gender, and food insecurity because the analyses are underpowered, these findings are outside the objective of this analysis and you did not look at specific confounders for these variables so these estimates cannot be interpreted in the same way as your main exposure variables (study arm).

Throughout the paper, suggest de-emphasizing lack of statistical significance. You weren’t adequately powered for statistical significance. Instead, would highlight preliminary evidence for a potential clinically meaningful effect that should be evaluated in a larger trial

Please add reference to ASCENT trial or clinicaltrial.gov number

369 – not sure the adherence monitoring via hair/urine really fits in here. I don’t think you are suggesting that these should be used programmatically. What are you are suggesting? Consider removing.

381 (devise, not device); also “farming” versus “faming”

Worth one final close proofread for typographical edits

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

Do you want your identity to be public for this peer review? If you choose “no”, your identity will remain anonymous but your review may still be made public.

For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLOS Glob Public Health. doi: 10.1371/journal.pgph.0001813.r003

Decision Letter 1

Megan Coffee

20 Jun 2023

PGPH-D-23-00372R1

The Feasibility, Acceptability, and Preliminary Impact of Real-Time Monitors and SMS on Tuberculosis Medication Adherence: Findings from a Mixed Methods Pilot Randomized Controlled Trial

PLOS Global Public Health

Dear Dr. Musiimenta

Thank you for submitting your manuscript to PLOS Global Public Health. After careful consideration, we feel that it has merit but does not fully meet PLOS Global Public Health’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

There has been substantial improvement of the paper and we appreciate this work. The paper is much closer to publication. Please see the comments and edits outlined by Reviewer 1. These comments would best guide the changes that are needed.

Please submit your revised manuscript by August 1. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at globalpubhealth@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pgph/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

We look forward to receiving your revised manuscript.

Kind regards,

Megan Coffee, MD, PhD

Academic Editor

PLOS Global Public Health

Journal Requirements:

Additional Editor Comments (if provided):

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: (No Response)

Reviewer #2: (No Response)

**********

2. Does this manuscript meet PLOS Global Public Health’s publication criteria? Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe methodologically and ethically rigorous research with conclusions that are appropriately drawn based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS Global Public Health does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Thank you to the authors for their revision. However, most of my concerns from the original review have not been addressed. In addition, now that I am able to see the questionnaires, I have some additional concerns (which I alluded to in the original review but was not able to assess without seeing the data collection forms).

1) My question about participants knowing investigators has not been addressed. Self-report does not alone lead to social desirability bias; knowing that the investigators are the ones who gave them the monitor does. (For example, if the Ministry of Health gave out the monitors and everyone hated them, and the investigators were perceived as being from an organization not aligned with the Ministry of Health, then people might feel perfectly comfortable complaining about them, so it would still be self-report but there would be less risk of social desirability bias).

2) The COREQ checklist has not been applied properly, and some of the information is still not in the paper. First, the checklist is supposed to reflect the qualitative component of the study, and therefore the information should only pertain to the interview procedures and participants, not the overall study population. Second, the information is supposed to be in the paper, not in the checklist (the checklist just says where to find it in the paper). The purpose of the checklist is to ensure that there is sufficient information in the paper to allow the reader to judge robustness and bias of the qualitative results.

3) My concerns over the lack of clarity in the tables about where information comes from have to some extent been clarified by attaching the questionnaires. However, seeing the questionnaires has not satisfied my concern about the authors having picked certain indicators to report and not others, and it makes me worry that they have cherry-picked the numbers that make the technology look acceptable. For example:

- Why does Table 2 report the number (%) of people in the weekly reminder group who would have preferred daily reminders but not the number (%) of people in the daily reminder group who would have preferred weekly reminders?

- Table 3 has “Perceived ease of use” reported as a n (%), but as far as I can see in the questionnaire, this question was asked as a Likert item, so it is not obvious what the reported value corresponds to.

- Also, the questionnaire actually asked four different questions about ease of use (opening, remember how to get pills, charging, traveling), so it is unclear why the authors only reported the first.

- The text at line 322 says “As indicated in Table 3, all PLTB completing the study (n=58; 100%) perceived the real-time monitor to be useful in reminding them to take their medications and implying care by healthcare workers.” However, this information is not in Table 3, which only reports ease of use, not usefulness. And I do not know what data support the statement “implying care by healthcare workers.”

4) The methods mention that the questionnaires and interview guides were developed based on the Unified Theory of Acceptance and Use of Technology model, which is one of the scientific strengths of this study. Looking at the questionnaire, the “Technology Adoption” section clearly reflects the UTAUT model and I think is the strongest aspect of the questionnaire since it is well grounded in a behavioral theory that can help interrogate the drivers of acceptability and adoption. However, the results from this section of the questionnaire are not really reported, except for isolated questions that have been picked for unclear reasons and collapsed into binary responses. I do not know why the authors chose to ignore this important section of their questionnaire – I realize it is possible that they are saving it for another paper. However, if that is the case, then I would not claim the UTAUT conceptual framework in the methods because the use of the framework is not at all evident in the results.

5) My concern about specifying data sources for the tables has been inadequately addressed. The Table 2 footnote should specify where all the data come from; I would suggest expanding the footnote to say, “Preference for SMS type/frequency was collected via patient questionnaires; all other data were collected from Wisepill device” (if that is the case). Table 3 should also have a similar footnote indicating where data came from.

6) I still do not understand what a message “sent unnecessarily” means. I understand that there were delayed messages when network connectivity failed, but why does that make the message unnecessary?

7) I do not understand added phrase at line 330 (“manifested inform of frequent communications)

Reviewer #2: Thank you authors for this updated manuscript. However, some things are still not that are not clear. The following suggestions and questions might further help in improving this manuscript.

Introduction

The current paper reports on the feasibility, Acceptability, and Preliminary Impact of Real-Time Monitors and SMS on Tuberculosis Medication Adherence: Findings from a Mixed Methods Pilot Randomized Controlled Trial [both the title and introduction line 119] - However, the study definition and metrics of the feasibility and impact are not stated or explained in the writeup.

Line 35 - Feasibility - What was its definition? How was this it assessed?

Line 171 - The primary outcome was .. kindly clarify on this, a couple of outcomes are given.

Impact - How was this it assessed?

Line 177 - the outcome measure of the acceptability of the intervention is not clear.

Line 40: "Among 66 participants " -- Update this to reflect 63 PLTB as indicated on line 269, line 277 and table 1 (line 281)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

Do you want your identity to be public for this peer review? If you choose “no”, your identity will remain anonymous but your review may still be made public.

For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLOS Glob Public Health. doi: 10.1371/journal.pgph.0001813.r005

Decision Letter 2

Megan Coffee

25 Sep 2023

PGPH-D-23-00372R2

The Feasibility, Acceptability, and Preliminary Impact of Real-Time Monitors and SMS on Tuberculosis Medication Adherence: Findings from a Mixed Methods Pilot Randomized Controlled Trial

PLOS Global Public Health

Dear Dr. Muslimenta: 

Thank you for submitting your manuscript to PLOS Global Public Health. After careful consideration, we feel that the paper is almost ready for publication and has merit but does not fully meet PLOS Global Public Health’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

The paper is close to ready for publication. I do not want to slow down publication but wanted to give you time to incorporate the helpful advice shared by Reviewers 4 and 5. If you are able to share the data with publication that would also be helpful.

Please submit your revised manuscript by October 6, if you are ready. You can take more time if needed, but I just wanted to stress that the paper is almost ready for publication. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at globalpubhealth@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pgph/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

We look forward to receiving your revised manuscript.

Kind regards,

Megan Coffee, MD, PhD

Academic Editor

PLOS Global Public Health

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments (if provided):

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

Reviewer #4: (No Response)

Reviewer #5: (No Response)

**********

2. Does this manuscript meet PLOS Global Public Health’s publication criteria? Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe methodologically and ethically rigorous research with conclusions that are appropriately drawn based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #4: Yes

Reviewer #5: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #4: Yes

Reviewer #5: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: Yes

Reviewer #4: Yes

Reviewer #5: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS Global Public Health does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #4: Yes

Reviewer #5: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: All of my comments have been addressed

Reviewer #2: (No Response)

Reviewer #4: Overall the authors report on the results of a small pilot RCT to assess the feasibility and acceptability of weekly vs daily vs standard of care SMS reminder with real-time adherence monitoring plus social support using an implementation science informed approach complete with relevant framework/theory. While these are important considerations, the study is hampered by the small sample size and the concurrent strategy components being evaluated (timing, type of message, social support, etc). While the study shows some interesting trends it is a bit hampered by the small sample size.

1. In terms of implementation outcomes, in addition to acceptability and feasibility, was reach considered. One challenge with DAT is its potential with perpetuating inequity. Especially as the study excluded individuals who were unable to demonstrate mobile/cellphone use/ownership or signal or ability to maintain and charge, these may be associated with sociodemographic characteristics. While the authors share some content analysis related to underlying SDoH,

2. Did the study support/provide airtime for participants in receiving messages? If not, why not? Is this a sustainable model?

3. How was the threshold for feasilibility of SMS delivery determined. 66% fidelity to SMS daily while in theory is a “majority,” operationally does not seem reliable enough to consider it feasible.

4. In terms of the Data Availability Statement, I am unclear about whether requests through the origin IRB constitutes “absence of restriction” as denoted by the Journal’s policy.

5. Finally, some of the statements regarding the results of the univariate and multivariate analyses seem a bit out of proportion to the statistical tests reported. It would be important to note that “trends” of higher adherence are observed, but are not necessarily statistically significant based on the p values described. I encourage the authors to caveat their findings a bit more, especially given the small sample size.

6. In the discussion (paragraph 2), many suggestions are made for additional implementation strategy components that more directly address underlying social and structural determinants as barriers for TB affected individuals. However, the logic around increasing “feasibility” of the SMS to social supporters by providing these additional targeted components (financial resources, livelihood support, etc) is unclear. Instead of positioning these novel strategies as a way to increase the feasibility of the SMS, it seems more appropriate to state that these would increase the primary outcome- adherence, and to acknowledge that they may do that with or without the SMS intervention.

7. In conjunction with comment above, it also might be more appropriate to state that the SMS intervention is not designed to target social and structural determinants of health and so a future consideration would be linking this strategy to one that does in order to maximize not just feasibility but overall effect.

8. Paragraph starting line 415 requires references.

9. Discussion paragraph starting at line 424 could be improved by differentiating the reviews/prior literature on real-time adherence monitoring linked to SMS vs other SMS reminder systems.

Reviewer #5: The authors report on the results of a pilot randomized controlled trial among patients initiating treatment for drug-sensitive TB in a low-resource setting with high HIV co-infection in Uganda. It was a three arm ‘pilot’ trial, based on prior informative studies, whereby all participants received real-time electronic adherence monitors and were randomized (1:1:1) to daily or weekly SMS reminders to both patients and their identified social supporters for the first 3 months followed by only triggered SMS sent when the pill bottle was not opened for the remainder of the treatment course, vs a control arm that did not use SMS but dose monitor bottles only. They assessed acceptability, feasibility, and percent adherence levels by the real-time monitors as a primary outcome. As a 'pilot' RCT, it was not powered to detect a meaningful clinical outcome. Overall, this appears to be a well conducted study and is well presented. The inclusion of text messages to social supporters is interesting and appears to be an advancement over previous versions these authors have studied in terms of integrated adherence support linked to the monitoring. This use of the dose monitor plus texting approach in TB and including social supporters in receiving SMS messages is novel and should be of interest to people running TB programs and looking for alternative to in-person DOT. There are no major weaknesses I am concerned about, but a few minor suggestions.

Minor

Title/Abstract:

The title and/or abstract should include the study location/country for better context.

People/persons – suggest choose one. Also, PLTB often stands for Pleural TB in the existing literature, if not a standard acronym, perhaps avoid it or select a unique one.

One concern is that if SMS messages are used as ‘reminders’ for daily dosing, then 80% ‘sent’ rate would not be considered adequately feasible, as 20+ % lack of reminders may negatively influence adherence rates if they are in fact relied upon as reminders. If >80% of adherence is an expected minimum level for clinically effective treatment, this already starts at the bottom end? Also, if 96% of the texts were sent to social reports about adherence data, but this is more than the success rate to the patients, its hard to understand how the not sent messages to patients would be reported to social supporters? That said, the higher adherence levels in the daily SMS vs other arms is reassuring. Perhaps this can be discussed.

If all PLTB as stated found the intervention useful, then why and what additional features need to be included to overcome concerns of TB status disclosure and effects of poverty? I’m not sure this is a data derived statement.

Line 60 – Clarify “Only real-time monitoring creates the potential for intervening prior to the development of treatment failure and/or drug resistance” Clearly there are other ways to assess adherence and how the patients are doing prior to treatment failure or drug resistance.

Introduction:

Overall, it is well written and justified.

Line 82: Please provide a level and reference for the key statement “treatment adherences remain a challenge”, since this is core to the purpose of the study.

Study Design and Setting are fairly well described, but please include more details on standard of care adherence support, since this is critical context to the additional or interactive effects of the study interventions. For instance, what adherence training or support is given upfront. And if patients are seen in clinic/person every 2 weeks, what is the purpose of the weekly ‘reminder’ (not dosing which is daily, and not appointments, which are biweekly?).

Inclusion criteria – includes only people that can text (see below re estimating cellphone access and ability). If purposive sampling was used, would the assessed/screened represent the whole clinic population or was there screening bias? This is important in estimating accessibility for the intervention in the whole clinic context.

Line 153: please indicate which way purposive sampling was used to skew gender from clinic norms, and any other factors that may have influence recruitment bias. Consecutive would provide better whole populations estimates for factors related to inclusion criteria.

The Wisepill technology is fairly well described. Perhaps discussion of if separate SIM cards are required or if they are linked to patients phones, and which networks can be included, would be additionally helpful.

Line 198: Please include more information on who the social supporters were (e.g. inclusion/exclusion criteria). If they were required for all participants (and how many might not have met this criteria) and what their roles were given that they were ‘not given specific instructions’ (authors only state they explained expectations, but no what those were). See disclosure issue below as well.

Line 231: Loss to follow-up not included, therefore per-protocol study (vs ITT).

Line 236: ITT secondary analysis (it might be clearer to describe PP vs ITT upfront as its mentioned in the discussion)

Line 281: What is meant by social supporters’ co-infection with HIV?

Table 1: Given the question was asked of PLTB if they had ‘enough social support’, it would be interesting given the nature of the intervention to describe the experiences of the subgroup who initially reported ‘not enough social support’ at baseline and if there was any finding worth exploring in future innovations or studies.

Disclosed TB status – please explain how can 14-20% not have disclosed to anyone other than a healthcare provider be but all identified social supporters to receive texts?

Line 291: All found SMS easy to use. Is this selection bias? What is the baseline literacy and texting rate in the clinic population?

Line 295: States SMS reminders occurred when the electronic adherence monitor was opened. But isn’t the point of a reminder to occur before medication is taken? Sentence may need clarification.

Line 298: Yes, since the SMS text are medication ‘reminders’ one would expect daily reminders timed with dosing schedules. This was confirmed by patients in line 302. Note, HIV studies that use weekly texts were not reminders, they were checkins, or informational messages. The sentence in line 298 has a wording issue stating “SMS reminders to triggered SMS reminders” What does this mean?

Interesting finding about preferences of personalized messages to default ‘reminders’.

Table 2

As above, if only 80% of medication reminders are sent/received as expected, this means they would not be feasible/reliable as ‘dose reminders’ as this is below desired adherence levels? (albeit they may have other general benefits?)

SMS notifications and social supporters – this is the most novel and fascinating part of the study and is well described. The financial and social support delineation is very interesting.

Real-time adherence monitor – patient acceptability and ease of use is encouraging. However, data on the clinic population as a whole would be important as inclusion criteria may have excluded less literate and technically capable patients.

Table 3 is well presented and contains useful technical and contextual information for the readers.

Discussion of risks:

Since patients reported usefulness of the SMS to remind them to take their daily medications, discuss the risk of the 20% delayed or not delivered reminders. Are there alternatives, or does the data indicated it doesn’t matter as good habits are formed?

Table 4 has excellent illustrative examples of quotations for context.

Primary adherence data is well presented.

Discussion

The discussion is balanced and reflects the key findings. Perhaps accessibility/acceptability is overstated if intended to reflect the whole PLTB clinic population. What about the others, how would they be treated or supported in such a program?

A larger trial is recommended. Which features would the authors recommend? It seems to me the weekly ‘reminders’ arm could be discontinued due to lower effect and patient preference compared to daily. This would be a reasonable conclusion to include.

The involvement and experience of social supporters via SMS is novel and interesting.

Line 431 states this technology can keep PLTB connected with healthcare workers, but it wasn’t clear from this study how that was the case (vs social supporters).

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

Do you want your identity to be public for this peer review? If you choose “no”, your identity will remain anonymous but your review may still be made public.

For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Haron Gichuhi

Reviewer #4: No

Reviewer #5: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLOS Glob Public Health. doi: 10.1371/journal.pgph.0001813.r007

Decision Letter 3

Megan Coffee

8 Nov 2023

The Feasibility, Acceptability, and Preliminary Impact of Real-Time Monitors and SMS on Tuberculosis Medication Adherence in Southwestern Uganda: Findings from a Mixed Methods Pilot Randomized Controlled Trial

PGPH-D-23-00372R3

Dear Dr Musiimenta

We are pleased to inform you that your manuscript 'The Feasibility, Acceptability, and Preliminary Impact of Real-Time Monitors and SMS on Tuberculosis Medication Adherence in Southwestern Uganda: Findings from a Mixed Methods Pilot Randomized Controlled Trial' has been provisionally accepted for publication in PLOS Global Public Health.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact globalpubhealth@plos.org.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Global Public Health.

Best regards,

Megan Coffee, MD, PhD

Academic Editor

PLOS Global Public Health

***********************************************************

Reviewer Comments (if any, and for reference):

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #4: All comments have been addressed

Reviewer #5: All comments have been addressed

**********

2. Does this manuscript meet PLOS Global Public Health’s publication criteria? Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe methodologically and ethically rigorous research with conclusions that are appropriately drawn based on the data presented.

Reviewer #4: Yes

Reviewer #5: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #4: Yes

Reviewer #5: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #4: Yes

Reviewer #5: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS Global Public Health does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #4: Yes

Reviewer #5: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #4: (No Response)

Reviewer #5: My comments have been addressed.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

Do you want your identity to be public for this peer review? If you choose “no”, your identity will remain anonymous but your review may still be made public.

For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #4: No

Reviewer #5: Yes: Richard Lester

**********

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Checklist. Reporting checklist for randomised trial.

    (DOCX)

    S2 Checklist

    (DOCX)

    S1 Appendix. Univariable and multivariate analysis of adherence across arms.

    (DOCX)

    S1 File. Trial protocol.

    (DOC)

    S1 Text. Questionnaire packet—study title: Real time tuberculosis medication adherence intervention in rural southwestern Uganda.

    (DOC)

    Attachment

    Submitted filename: PGPH-D-23-00372_Feedback to reviewers_12th May.docx

    Attachment

    Submitted filename: PGPH-D-23-00372_Response to Reviewers.docx

    Attachment

    Submitted filename: PGPH-D-23-00372-R3 Response.docx

    Data Availability Statement

    Data from this study contain sensitive patient information. Also, sharing this data breach the compliance with the protocol approved our research ethics board. However, de-identified individual data that supports the results will be shared following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Committee (REC), as applicable, and executes a data use/sharing agreement with Mbarara University of Science and Technology (MUST). Researchers may apply for data access by contacting the corresponding author or the MUST Research Ethics Committee at sec@rec.must.ac.ug.


    Articles from PLOS Global Public Health are provided here courtesy of PLOS

    RESOURCES